89bio

Powerful Science – Meaningful Medicines – Changing Lives

89bio was founded in 2018, is headquartered in San Francisco, United States, lists 11–50 employees, and has $60.0M in recorded funding across 1 round.

Headquarters
San Francisco
Employees
11–50
Founded
2018
Business Model
B2B
Website
89bio.com
Total Funding
$60.0M
Last Round
$60.0M Series AOct 2018
Rounds
1

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 1 funding round for this company. The full record is or through the API.

About

89bio is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for patients with liver and cardiometabolic diseases. Its lead candidate, pegozafermin, is an investigational glycopegylated FGF21 analog being evaluated for metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). The company targets FGF21, a metabolic hormone that regulates energy expenditure and glucose and lipid metabolism, as a treatment path for people with these conditions.

Summary

89bio is a Biotech company based in San Francisco, United States, founded in 2018. It lists 11–50 employees. It has raised $60.0M in total across 1 round, most recently a $60.0M Series A round in Oct 2018.

Tech & App Stack

5 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series ASeries AOct 2018
$60.0M

Similar Companies

Paratek PharmaceuticalsAcquired

Paratek Pharmaceuticals develops and delivers innovative treatments for serious infectious diseas...

Boston, United States201–500Biotech, Healthcare
ConvertibleTotal funding$1.8BApr 2018
Sana BiotechnologyIPO

Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

Seattle, United States201–500Biotech, Healthcare
Series DTotal funding$1.4BJun 2020
Abogen Biosciences

Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...

Suzhou, China201–500Biotech, Drug Discovery
Extension RoundTotal funding$1.2BNov 2021
Alnylam PharmaceuticalsIPO

Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...

Cambridge, United States1001–5000Biotech, Genomics
Corporate RoundTotal funding$1.0BApr 2020
Tiantan Biological / China Biologic (泰邦生物集团)

China's leading blood products manufacturer

Beijing, China1001–5000Biotech, Healthcare
Growth EquityTotal funding$5.1BAug 2022
Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

89bio on Indexed.vc
<a href="https://indexed.vc/companies/89bio"><img src="https://indexed.vc/api/badge/company/89bio" alt="89bio on Indexed.vc" width="260" height="76" /></a>